Study on the varieties included in the <italic style="font-style: italic">List of Overseas New Drugs Urgently Needed in Clinic</italic> in China and the optimization strategy

JIANG Feng; TIAN Kan

doi:10.6039/j.issn.1001-0408.2023.01.02

您当前的位置：

首页 >

文章列表页 >

Study on the varieties included in the List of Overseas New Drugs Urgently Needed in Clinic in China and the optimization strategy

更新时间：2023-02-22

- Study on the varieties included in the List of Overseas New Drugs Urgently Needed in Clinic in China and the optimization strategy
- ZHONGGUO YAOFANG Vol. 34, Issue 1, Pages: 7-11(2023)
- 作者机构：
  
  1.南京中医药大学卫生经济管理学院，南京　210023
  2.南京中医药大学养老服务与管理学院，南京　210023
- 作者简介：
- 基金信息：
- DOI：10.6039/j.issn.1001-0408.2023.01.02
  CLC： R95
- Published：15 January 2023，
  
  Received：05 September 2022，
  
  Revised：04 December 2022，
扫描看全文
蒋丰,田侃.我国《临床急需境外新药名单》纳入品种及优化策略研究 ^Δ[J].中国药房,2023,34(01):7-11.

JIANG Feng,TIAN Kan.Study on the varieties included in the List of Overseas New Drugs Urgently Needed in Clinic in China and the optimization strategy[J].ZHONGGUO YAOFANG,2023,34(01):7-11.
蒋丰,田侃.我国《临床急需境外新药名单》纳入品种及优化策略研究 ^Δ[J].中国药房,2023,34(01):7-11. DOI： 10.6039/j.issn.1001-0408.2023.01.02.

JIANG Feng,TIAN Kan.Study on the varieties included in the List of Overseas New Drugs Urgently Needed in Clinic in China and the optimization strategy[J].ZHONGGUO YAOFANG,2023,34(01):7-11. DOI： 10.6039/j.issn.1001-0408.2023.01.02.

摘要

目的

对我国《临床急需境外新药名单》的纳入品种及优化策略进行研究，以更好地满足患者用药需求。

方法

对我国《临床急需境外新药名单》的发布过程、临床急需境外新药的品种特点与属性、《临床急需境外新药名单》落实过程中存在的问题等进行分析，并就如何优化完善《临床急需境外新药名单》提出对策建议。

结果与结论

《临床急需境外新药名单》的发布过程大致可分为孕育阶段、准备阶段和实施阶段。3批临床急需境外新药的治疗领域相对集中于内分泌和代谢病、肿瘤、皮肤疾病，纳入的73个品种中已经有50个品种获批上市，26个品种被纳入医保，4个品种被纳入《鼓励仿制药品目录》。当前我国临床急需境外新药还存在短缺监测制度有待建立健全、与医保的联动减弱、鼓励仿制力度不足等问题。应当加强临床急需境外新药短缺监测的部门协同联动，建立以临床价值为导向的医保支付体系，完善鼓励仿制临床急需境外新药的配套激励机制。

Abstract

OBJECTIVE

To study the variety included in the

List of Overseas New Drugs Urgently Needed in Clinic

in China and optimization strategy， in order to better meet the needs of patients.

METHODS

The release process of

List of Overseas New Drugs Urgently Needed in Clinic

， the characteristics and attributes of the new drugs urgently needed abroad， and the problems in the implementation process were all analyzed to put forward some suggestions for optimizing the

List of Overseas New Drugs Urgently Needed in Clinic

RESULTS & CONCLUSIONS

The release process of the

List of Overseas New Drugs Urgently Needed in Clinic

was roughly divided into incubation stage， preparation stage and implementation stage. The treatment fields of 3 batches of overseas new drugs urgently needed in clinic were relatively concentrated on endocrine and metabolic diseases，tumor and skin diseases. Of included 73 varieties， 50 varieties have been approved for market，and 26 varieties have been included in the medical insurance， 4 varieties were included in the

Catalogue of Encouraged Generic Drugs

. At present， there are still some problems in our country， such as the shortage monitoring system needs to be established and improved； the linkage with medical insurance is weakened； the encouragement of generic drugs is insufficient. It is necessary to strengthen the cooperation of monitored departments in the shortage of new overseas drugs，establish a medical insurance payment system oriented by clinical value， and improve the incentive mechanism to encourage the imitation of overseas new drugs urgently needed in clinic.

关键词

临床急需境外新药名单品种优化策略

Keywords

varietyoptimization strategy

references

国家药品监督管理局药品审评中心.关于发布第一批临床急需境外新药名单的通知[EB/OL].（2018-11-01）[2022-05-18]. https：//www.cde.org.cn/main/news/viewInfoCommon/21de8acd6c395746b041b2ad93eb5c43https://www.cde.org.cn/main/news/viewInfoCommon/21de8acd6c395746b041b2ad93eb5c43.

国家药品监督管理局.关于进口化学药品通关检验有关事项的公告：2018年第12号[EB/OL].（2018-04-26）[2022-05-19]. https：//www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180426144301235.htmlhttps://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180426144301235.html.

国家药品监督管理局.关于优化药品注册审评审批有关事宜的公告：2018年第23号[EB/OL].（2018-05-23）[2022-05-20]. https：//www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180523110601517.htmlhttps://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20180523110601517.html.

国家药品监督管理局.关于临床急需境外新药审评审批相关事宜的公告：2018年第79号[EB/OL].（2018-10-30）[2022-05-20]. https：//www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20181030171201646.htmlhttps://www.nmpa.gov.cn/zhuanti/ypqxgg/ggzhcfg/20181030171201646.html.

王雪，赵聪，许淑红，等.我国罕见病用药可及性现状分析[J].中国临床药理学杂志，2021，37（8）：1026-1032.

崔积钰，韩优莉.基于中美日新药上市现状对比的抗肿瘤新药发展策略研究[J].中国卫生政策研究，2021，14（8）：52-59.

国家药品监督管理局药品审评中心.关于发布《境外已上市境内未上市药品临床技术要求》的通告：2020年第29号[EB/OL].（2020-10-16）[2022-05-25]. https：//www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20201016145016178.htmlhttps://www.nmpa.gov.cn/xxgk/ggtg/qtggtg/20201016145016178.html.

李静，陈文，蒋虹丽.短缺药品供应保障的地方实践进展及启示[J].中国卫生资源，2021，24（4）：472-475，487.

刘青泽，韩月，朱虹，等.国内外短缺药品监测预警体系对比分析[J].中国药业，2019，28（18）：1-4.

李立红，杨小丽.论平等权视域下罕见病药品可及性的制度困境[J].医学争鸣，2016，7（6）：59-62.

刘鑫，李建涛，张鹏霄，等.中国孤儿药现状及与国外对比分析研究[J].中国药学杂志，2019，54（10）：839-846.

吴方，周迎波，崔茉莉.国际环境下的我国孤儿药产业发展策略研究[J].中国医药工业杂志，2015，46（4）：428-434.

FDA. Orange book：approved drug products with therapeutic equivalence evaluations[EB/OL].（2022-05-31）[2022-06-01]. https：//www.accessdata.fda.gov/scripts/cder/ob/index.cfmhttps://www.accessdata.fda.gov/scripts/cder/ob/index.cfm.

张帆，杨穆瑶，张志娟，等.中国医药创新面临的挑战及其应对[J].医学与哲学，2022，43（2）：1-6.

丁锦希，李轶，韩晓睿，等.国家医保目录动态调整机制的改革成效与发展思路[J].中国医疗保险，2021（5）：40-46.

王冬.基于价值医疗的医疗保险支付体系改革创新[J].社会保障评论，2019，3（3）：92-103.

王圣鸣，田侃，王紫红.我国鼓励仿制药品目录政策趋势研究[J].中国药房，2021，32（17）：2053-2058.

FDA.Competitive generic therapies[EB/OL].（2020-06-05）[2022-06-03]. https：//www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapieshttps://www.fda.gov/regulatory-information/search-fda-guidance-documents/competitive-generic-therapies.

李晓秋，余晨.论新《专利法》中药品专利链接制度的确立及完善[J].中国科技论坛，2022（1）：131-138，160.

Views

下载量

CSCD

Alert me when the article has been cited

提交

Tools

Publicity Resources

No data

Related Author

No data

Related Institution

No data

Address：8/F,129 Daping Main Street,Yuzhong District,Chongqing 400042,P.R.China
Technical support is provided by Beijing Founder Electronics co., LTD 渝ICP备15012710号公网安备50010302001817
It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.

⁰

Study on the varieties included in the List of Overseas New Drugs Urgently Needed in Clinic in China and the optimization strategy

DOI：10.6039/j.issn.1001-0408.2023.01.02

摘要

Abstract

关键词

Keywords

references